Aditi Shah
Analyst/Associate at Analysis Group
Data updated
Research Footprint
Aditi Shah appears in 5 tracked papers (2013–2025), most studied alongside Ketamine and Esketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (1200 citations).
Frequent co-authors: Kruti Joshi, Maryia Zhdanava and Dominic Pilon.
Background & Research
Aditi Shah is a researcher at Analysis Group whose publications focus on real-world outcomes, healthcare utilization, costs, and access related to esketamine nasal spray and other treatments for treatment-resistant depression. She is listed as an author on multiple papers in the psychiatric and pharmacoeconomic literature, including studies of ketamine/esketamine in depression and suicidality. Based on the available evidence, she appears to be an industry-affiliated health economics/real-world evidence author rather than a clinical psychiatrist.
Key Impact
She appears on multiple real-world evidence and health economics papers on ketamine/esketamine for treatment-resistant depression and suicidal ideation, contributing to the evidence base around novel psychiatric treatments.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Aditi Shah is associated with.